Dynavax drops Tolamba after another miss.(Monday, May 19)

Citing insurmountable variability issues, Dynavax Technologies Corp. is shelving Toll like receptor 9 (TLR9) agonist Tolamba after the drug failed to show statistical significance over placebo in reducing the nasal symptoms in ragweed allergy sufferers. The Berkeley, Calif. based firm, instead, will direct resources to other areas of its pipeline, …